Sobi’s climate targets approved by SBTi
Sobi’s commitment to sustainability has reached an important milestone: our near-term climate targets have been validated and approved by the Science Based Targets initiative (SBTi). This approval confirms that our near-term targets for scope 1 and 2 align with the ambition to limit global warming to 1.5°C, and our scope 3 target is compatible with limiting global warming well below 2°C, all in line with the Paris Agreement.
“This achievement is the result of great collaboration among many colleagues who have helped define Sobi's climate challenge and identify solutions and best practices. SBTi’s approval not only validates our efforts but also strengthens our credibility with key stakeholders, including customers and investors,” said Cecilia Nord, Global Head of Sustainability.
Taking meaningful climate action
In late 2024, Sobi established a set of global climate targets to drive progress within our operations and value chain. These targets focus on reducing emissions while engaging key partners in shared climate action. With SBTi’s approval, we further strengthen our ability to integrate sustainability across our business and contribute to a healthier planet.
Under this framework, Sobi commits to:
• Reducing CO₂ emissions from our operations by 40% by 2029, compared to 2023 levels.
• Engaging 65% of suppliers across Sobi’s key supplier categories to set science-based targets by 2029.
While we have already taken steps to improve our climate performance, this approval accelerates our efforts. We are now implementing a structured roadmap to drive measurable progress, focusing on reducing emissions across our operations, including our sites and company car fleet.
A commitment to transparency and progress
Sobi’s sustainability efforts are guided by science and a commitment to transparency. As customers, investors, and regulators increasingly expect robust climate commitments, securing external validation reinforces our credibility and ensures clear communication of our goals.
By acting today, we strengthen our ability to meet evolving expectations, drive long-term impact, and contribute to a more sustainable future.
We provide access to innovative treatments that transform life for people.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present current and past media releases, images and videos.
- About
- Therapeutic areas
- Medicines
- Stories
- Sustainability
- Careers
- Investors
- Media
- English
- Swedish